Navigation Links
Stematix™ Obtains Exclusive License to Regenexx™ Stem Cell Procedure Treating Musculoskeletal Diseases in Latin America

License Strengthens Stematix's Regenerative Treatments

Houston, TX (PRWEB) October 23, 2009 -- Stematix Inc., announced today it has signed an exclusive royalty-bearing license agreement, for the Latin American territory, to use an innovative process that rapidly grows a patients own adult stem cells to treat a variety of musculoskeletal diseases.

Stematix which is establishing international therapy clinics in public-private partnerships to provide near-term and approved stem cell treatments for hundreds of millions of patients that could potentially benefit.

Through its and its partners' industry know-how and experience, Stematix has developed a suite of commercial products and solutions to help the stem cell research community and also global partners establish world-class stem cell therapy, banks and therapy clinics in a cost-effective and timely manner.

The licensed procedure has been developed by Regenerative Sciences, LLC, a Colorado-based company focused on developing a medical procedure for the treatment of chronic orthopedic conditions. Known under the name Regenexx™, the innovative outpatient procedure takes stem cells from an individual's bone marrow, isolates mesenchymal stem cells (which can grow into bone, tendon, muscle, ligament and cartilage), cultures them in a solution containing unique elements from the individual's own blood, and generates millions of stem cells over two to three weeks. These cells are then re-injected into the person's joints or bones in an office procedure to assist in tissue healing and restoration of bone and cartilage. The Regenexx Procedure has helped many patients avoid more risky and costly surgical intervention.

Additionally, Regenerative Sciences' founder and CEO, Christopher Centeno, M.D., has agreed to serve as a consultant to Stematix Inc. in the area of stem cell therapy in orthopedics. Dr. Centeno is an international expert in musculoskeletal, spinal and neurological injury. Dr. Centeno will continue to assist Stematix in using mesenchymal stem cell isolation and transplantation methods abroad in the lab and clinical setting. He will also train personnel in Colorado in mesenchymal stem cell isolation, preparation and transplantation methods.

David C. Bonner, Ph.D., Chairman and CEO of Stematix, said, "We at Stematix are excited to be working with Regenexx, the leaders in applied regenerative medicine for orthopedics. We anticipate that this cutting edge, proven treatment will provide needed care for many patients in clinics established in Latin America. We are working toward a first clinic in Argentina during 2010. The expertise and experience of Dr. Centeno and Dr. Schulz will be invaluable in establishing our clinic in Argentina, and we look forward to incorporating advances in the treatment methodology that the Regenexx clinic in Denver will lead. "

Dr. Centeno said, "I look forward to working with Stematix and their team to bring Regenerative Science's important stem cell innovations to a worldwide audience of doctors and patients. I'm especially excited about Stematix's relationships and its expanding presence in Latin America."

About Stematix™, Inc.
Stematix is a regenerative medicine therapy company poised to accelerate safe and effective use of stem cell therapies globally. Stematix is establishing international therapy clinics in public-private partnerships that provide near-term and approved stem cell treatments for hundreds of millions of patients that could potential benefit. Through industry partnerships, Stematix has developed a suite of commercial products and solutions to help the stem cell research community and also global partners establish word-class stem cell therapy, banks and therapy clinics in a cost-effective and timely manner.

For more information, please visit: Regenexx .

Ms. Timmie Wang, Vice President Business Development
T: +1-713-212-0671

Regenerative Sciences.
Carl R. Measer, MBA, Chief Operating Officer
T: 303-429-6448

# # #

Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Karmanos Cancer Institute Immunology Researcher Obtains Nearly $1 Million National Institutes of Health Grant
2. Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government
3. Simcere Pharmaceutical Group Invested Company Obtains Production License for H1N1 Flu Vaccine
4. Occlutech and IZASA Obtains Favourable Ruling in Proceeding Initiated by AGA Medical in Spain
5. Imagenetix (IAGX) Obtains Apology
6. Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device
7. China Sky One Medical, Inc. Obtains Renewal of GMP Certificate
8. RainEarth Obtains Patent Approvals for Its Core Technology
9. China Sky One Medical, Inc. Obtains Production License Renewal for Sumei Slim Patch
10. China Sky One Medical, Inc. Obtains SFDA Approval for Diclofenac Sodium Eye Drops
11. Occlutech Obtains CE Mark for the new Generation PFO & ASD Occluders
Post Your Comments:
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology: